NCT00724529View on ClinicalTrials.gov

Post Marketing Surveillance of Remicade

CompletedOBSERVATIONAL
Enrollment

938

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Crohn's DiseaseAnkylosing Spondylitis
Interventions
BIOLOGICAL

Infliximab

Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.

All Listed Sponsors
lead

Janssen Korea, Ltd., Korea

INDUSTRY

NCT00724529 - Post Marketing Surveillance of Remicade | Biotech Hunter | Biotech Hunter